Baxdrostat Bioavailability and Bioequivalence Study

NCT05963009 | Completed Phase 1 FDA Drug

• 1 other identifier: CIN-107-112
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this study was to compare the characteristics of a new tablet formulation versus an oral solution of CIN-107 (baxdrostat) in terms of CIN-107 levels over time in the blood and to compare the effect of food on these parameters in healthy volunteer participants who received the CIN-107 tablet under fed versus fasted conditions.

Conditions

Hypertension

Keywords

pharmacokinetics (PK); food effect; bioavailability

Outcome Measures

Primary Outcomes (7)

• Incidence of treatment emergent adverse events following single oral doses of CIN-107 tablet and oral solution.

  The safety and tolerability of CIN-107 will be assessed throughout the study based on quantitation of adverse events that occur following oral doses of CIN-107 tablet and oral solution.

  0 to 23 days after dosing

• Maximum concentration [Cmax] following administration of a tablet formulation of CIN-107 compared to Cmax following administration of the oral solution.

  Cmax will be determined for CIN-107 and any other measured metabolites for participants given each formulation of baxdrostat; relative bioavailability will be evaluated by comparing these parameters between patients given the solution versus the tablet.

  0 to 21 days after dosing

• Cmax of CIN-107 following administration of the tablet formulation under fed versus fasted conditions.

  Cmax will be determined for CIN-107 and any other measured metabolites for participants given baxdrostat under fed versus fasted conditions; food effect will be evaluated by comparing Cmax between participants under each condition.

  0 to 21 days after dosing

• Area under the curve [AUC] following administration of a tablet formulation of CIN-107 compared to AUC following administration of the oral solution.

  Area under the curve (AUC)0-∞ and AUC0-last will be determined for baxdrostat and any other measured metabolites for participants given each formulation of baxdrostat. Then relative bioavailability will be evaluated by comparing these AUC parameters between patients given the solution versus the tablet.

  0 to 21 days after dosing

• Time to maximum concentration [Tmax] of CIN-107 following administration of the tablet formulation under fed versus fasted conditions.

  Tmax will be determined for CIN-107 and any other measured metabolites for participants given baxdrostat under fed versus fasted conditions, and then food effect will be evaluated by comparing Tmax between participants under each condition.

  0 to 21 days after dosing

• AUC of CIN-107 following administration of the tablet formulation under fed versus fasted conditions.

  Area under the curve (AUC)0-∞ and AUC0-last will be determined for CIN-107 and any other measured metabolites for participants given baxdrostat under fed versus fasted conditions, and then food effect will be evaluated by comparing AUC between participants under each condition.

  0 to 21 days after dosing

• Tmax following administration of a tablet formulation of CIN-107 compared to Tmax following administration of the oral solution.

  Tmax will be determined for CIN-107 and any other measured metabolites for participants given each formulation of baxdrostat.

  0 to 21 days after dosing

Secondary Outcomes (1)

• Angiotensin converting enzyme (ACE) levels following single doses of CIN-107.

  0 to 21 days after dosing

Study Arms (3)

Baxdrostat oral solution

EXPERIMENTAL

5 mg CIN-107 oral solution in a fasted state

Drug: baxdrostat (formerly CIN-107) oral solution

Baxdrostat tablet (fasted state)

EXPERIMENTAL

5 mg CIN-107 tablet(s) in a fasted state

Drug: baxdrostat (formerly CIN-107) oral solution

Baxdrostat tablet (fed state)

EXPERIMENTAL

5 mg CIN-107 tablet(s) in a fed state (standard high fat meal)

Drug: baxdrostat (formerly CIN-107) oral solution

Interventions

baxdrostat (formerly CIN-107) oral solution DRUG

5 mg single dose of baxdrostat given as either a solution or tablet in either the fed or fasted state, depending on the arm of the study

Also known as: baxdrostat (formerly CIN-107) tablet

Baxdrostat oral solution; Baxdrostat tablet (fasted state); Baxdrostat tablet (fed state)

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy subjects between the ages of 18 and 55 years, inclusive, in good health based on medical and psychiatric history, physical examination, electrocardiogram (ECG), vital signs (seated and orthostatic), and routine laboratory tests (blood chemistry, hematology, coagulation, and urinalysis).
• Body mass index (BMI) between 18 and 30 kg/m2, inclusive.
• Nonsmokers who have not used nicotine-containing products for at least 6 months prior to Screening.
• Male subjects with female partners of child-bearing potential must agree to use two medically accepted, highly effective methods of birth control from Day 1 through 90 days after the final dose of study drug.
• Male subjects must agree to abstain from sperm donation from Day 1 through 90 days after administration of the final dose of study drug.
• Female subjects with male partners must be surgically sterile (hysterectomy and/or bilateral oophorectomy), postmenopausal for at least 1 year (with follicle-stimulating hormone in postmenopausal range), or agree to use two medically accepted, highly effective methods of birth control from Day -14 until 60 days following the final dose of study drug.
• Able to understand and willing to comply with study procedures and restrictions (including confinement to the clinical unit, fasting and meal requirements, and restrictions on physical activity, use of recreational drugs or alcohol, and medications), and provide written informed consent according to institutional and regulatory guidelines.

You may not qualify if:

• Actively participating in an experimental therapy study; received experimental therapy with a small molecule other than CIN-107 within 30 days of the first dose of study drug, or 5 halflives, whichever is longer; or received experimental therapy with a large molecule within 90 days of the first dose of study drug, or 5 half-lives, whichever is longer.
• A personal or family history of long QT syndrome, Torsades de Pointes, or other complex ventricular arrhythmias, or family history of sudden death.
• History of, or current, clinically significant arrhythmias as judged by the Investigator, including ventricular tachycardia, ventricular fibrillation, atrial fibrillation, sinus node dysfunction, or clinically significant heart block. Subjects with minor forms of ectopy (eg, premature atrial contractions) are not necessarily excluded.
• Prolonged QTcF (\>450 msec).
• Seated blood pressure higher than 150/90 mmHg or lower than 90/50.
• Resting heart rate higher than 100 bpm or lower than 50 bpm.
• Temperature (T) greater than 37.6 C (99.68 F), measured orally, and respiration rate less than 12 or greater than 20 breaths/minute.
• Postural tachycardia (i.e. \>30 bpm upon standing) or orthostatic hypotension (i.e., a fall in systolic blood pressure (SBP) of ≥20 mm Hg or diastolic blood pressure (DBP) of ≥ 10 mm Hg when a person assumes a standing position).
• Serum potassium \> upper limit of normal of the reference range (ULN) and serum sodium \< lower limit of normal of the reference range (LLN).
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) values \> 1.2 ULN.
• Positive for human immunodeficiency virus (HIV) antibody, hepatitis C virus (HCV) antibody, or Hepatitis B surface antigen (HBsAg).
• Any other clinical laboratory values which are meaningfully outside of normal limits (based on laboratory normal range) in the opinion of the Investigator.
• A known history of porphyria, myopathy, or an active liver disease.
• Evidence or history of any clinically significant immunologic, hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, musculoskeletal, hepatic, psychiatric, neurologic, or allergic disease (including clinically significant or multiple drug allergies); surgical conditions; cancer (with the exception of basal or squamous cell carcinoma of the skin and cancer that resolved or has been in remission for \>5 years prior to Screening); or any condition that, in the Investigator's opinion, may confound study procedures or results, impact subject safety, or interfere with the absorption, distribution, metabolism, or excretion of the study drug (appendectomy allowed, cholecystectomy prohibited).
• Use of any prescription medications (including topicals) or over-the-counter medications (other than occasional use of acetaminophen or nonsteroidal anti-inflammatory drugs, such as ibuprofen or naproxen, according to the package insert); herbal supplements; dietary supplements; or nutraceuticals within 14 days prior to the first dose of study drug, or 5 halflives, whichever is longer, or an unwillingness to refrain from these medications through discharge from the clinical unit. Note: Use of over-the-counter topical medications may be permitted in consultation with the Sponsor. In addition, medications for which 5 half-lives exceeds 14 days must be discussed with and approved by the Sponsor prior to subject enrollment.

Sponsors & Collaborators

• AstraZeneca: lead

Study Sites (1)

Medpace

Cincinnati, Ohio, 45227, United States

Location

Related Links

• Redacted CSR Synopsis

MeSH Terms

Conditions

Hypertension

Interventions

Solutions; Tablets

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Pharmaceutical Preparations; Dosage Forms

Study Officials

• L Vrishabhendra, MD

  Medpace, Inc.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Randomized Crossover between 1) oral solution, 2) tablet in the fasted state, and 3) tablet in the fed state

Study Record Dates

• First Submitted: July 3, 2023
• First Posted: July 27, 2023
• Study Start: March 11, 2020
• Primary Completion: April 29, 2020
• Study Completion: April 29, 2020
• Last Updated: August 14, 2023

Record last verified: 2023-08

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP
• Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• Access Criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Locations

US (1)